6 O
ADVERSE O
REACTIONS O
The O
following O
serious O
adverse O
reactions O
are O
discussed O
elsewhere O
in O
the O
labeling O
: O
* O
Severe O
cardiopulmonary B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
) O
] O
* O
Hypersensitivity B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
[ O
see O
Warnings O
and O
Precautions O
( O
5.2 O
) O
] O
EXCERPT O
: O
Most O
common O
adverse O
reactions O
( O
incidence O
> O
= O
0.5 O
% O
) O
are O
headache O
and O
nausea O
( O
6.1 O
) O
. O

To O
report O
SUSPECTED O
ADVERSE O
REACTIONS O
, O
contact O
Bracco O
Diagnostics O
Inc O
at O
1-800-257-5181 O
or O
FDA O
at O
1-800-FDA-1088 O
or O
www.fda.gov/medwatch O
6.1 O
Clinical O
Trials O
Experience O
Because O
clinical O
trials O
are O
conducted O
under O
widely O
varying O
conditions O
, O
adverse O
reaction O
rates O
observed O
in O
the O
clinical O
trials O
of O
a O
drug O
can O
not O
be O
directly O
compared O
to O
rates O
in O
the O
clinical O
trials O
of O
another O
drug O
and O
may O
not O
reflect O
the O
rates O
observed O
in O
practice O
. O

In O
completed O
clinical O
trials O
, O
a O
total O
of O
6307 O
adult O
subjects O
( O
128 O
healthy O
volunteers O
and O
6179 O
patients O
) O
received O
Lumason O
at O
cumulative O
doses O
ranging O
from O
0.2 O
to O
161 O
mL O
( O
mean O
10.5 O
mL O
) O
. O

Lumason O
was O
administered O
mainly O
as O
single O
or O
multiple O
injections O
; O
however O
, O
some O
subjects O
received O
infusion O
dosing O
. O

The O
majority O
( O
73 O
% O
) O
of O
subjects O
received O
Lumason O
at O
cumulative O
doses O
of O
10 O
mL O
or O
less O
. O

There O
were O
65 O
% O
men O
and O
35 O
% O
women O
, O
with O
an O
average O
age O
of O
59 O
years O
( O
range O
17 O
to O
99 O
years O
) O
. O

A O
total O
of O
4993 O
( O
79 O
% O
) O
subjects O
were O
Caucasian O
; O
192 O
( O
3 O
% O
) O
were O
Black O
; O
1053 O
( O
17 O
% O
) O
were O
Asian O
; O
33 O
( O
< O
1 O
% O
) O
were O
Hispanic O
; O
and O
36 O
( O
< O
1 O
% O
) O
were O
in O
other O
racial O
groups O
or O
race O
was O
not O
reported O
. O

In O
the O
clinical O
trials O
, O
serious O
adverse O
reactions O
were O
observed O
in O
2 O
subjects O
; O
one O
who O
experienced O
a O
hypersensitivity B-OSE_Labeled_AE
- I-OSE_Labeled_AE
type I-OSE_Labeled_AE
rash I-OSE_Labeled_AE
and O
near B-OSE_Labeled_AE
syncope I-OSE_Labeled_AE
symptoms O
and O
another O
who O
experienced O
anaphylactic B-OSE_Labeled_AE
shock I-OSE_Labeled_AE
shortly O
following O
Lumason O
administration O
. O

The O
most O
commonly O
reported O
adverse O
reactions O
among O
patients O
( O
occurring O
among O
at O
least O
0.2 O
% O
of O
patients O
) O
are O
listed O
below O
( O
Table O
1 O
) O
. O

Most O
adverse O
reactions O
were O
mild O
to O
moderate O
in O
intensity O
and O
resolved O
spontaneously O
. O

* O
occurring O
in O
at O
least O
0.2 O
% O
of O
patients O
Table O
1 O
. O

Adverse O
Reactions O
in O
Patients*n O
= O
6179 O
Number O
( O
% O
) O
of O
Patients O
with O
Adverse O
Reactions O
302 O
( O
4.9 O
% O
) O
Headache B-OSE_Labeled_AE
56 O
( O
0.9 O
% O
) O
Nausea B-OSE_Labeled_AE
34 O
( O
0.6 O
% O
) O
Dysgeusia B-OSE_Labeled_AE
19 O
( O
0.3 O
% O
) O
Injection B-OSE_Labeled_AE
site I-OSE_Labeled_AE
pain I-OSE_Labeled_AE
18 O
( O
0.3 O
% O
) O
Chest B-OSE_Labeled_AE
discomfort I-OSE_Labeled_AE
16 O
( O
0.3 O
% O
) O
Feeling B-OSE_Labeled_AE
Hot I-OSE_Labeled_AE
16 O
( O
0.3 O
% O
) O
Chest B-OSE_Labeled_AE
pain I-OSE_Labeled_AE
11 O
( O
0.2 O
% O
) O
Injection B-OSE_Labeled_AE
Site I-OSE_Labeled_AE
Warmth I-OSE_Labeled_AE
11 O
( O
0.2 O
% O
) O
6.2 O
Postmarketing O
Experience O
In O
the O
international O
postmarketing O
clinical O
experience O
and O
on-going O
clinical O
trials O
, O
serious O
adverse O
reactions O
have O
uncommonly O
been O
reported O
following O
administration O
of O
Lumason O
. O

Because O
these O
reactions O
are O
reported O
voluntarily O
from O
a O
population O
of O
uncertain O
size O
, O
it O
is O
not O
always O
possible O
to O
reliably O
estimate O
their O
frequency O
or O
establish O
a O
causal O
relationship O
to O
drug O
exposure O
. O

The O
serious O
adverse O
reactions O
include O
fatalities O
, O
especially O
in O
a O
pattern O
of O
symptoms O
suggestive O
of O
anaphylactoid B-OSE_Labeled_AE
/hypersensitivity O
reactions I-OSE_Labeled_AE
. O

Other O
serious O
reactions O
included O
arrhythmias B-OSE_Labeled_AE
and O
hypertensive B-OSE_Labeled_AE
episodes I-OSE_Labeled_AE
. O

These O
reactions O
typically O
occurred O
within O
30 O
minutes O
of O
Lumason O
administration O
. O

The O
risk O
for O
serious O
cardiopulmonary B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
may O
be O
increased O
among O
patients O
with O
unstable O
cardiopulmonary B-Not_AE_Candidate
conditions I-Not_AE_Candidate
( O
acute B-Not_AE_Candidate
myocardial I-Not_AE_Candidate
infarction I-Not_AE_Candidate
, O
acute B-Not_AE_Candidate
coronary I-Not_AE_Candidate
artery O
syndromes I-Not_AE_Candidate
, O
worsening B-Not_AE_Candidate
or O
unstable O
congestive I-Not_AE_Candidate
heart I-Not_AE_Candidate
failure I-Not_AE_Candidate
, O
or O
serious O
ventricular B-Not_AE_Candidate
arrhythmias I-Not_AE_Candidate
[ O
see O
Warnings O
and O
Precautions O
( O
5.1 O
] O
) O
. O

